Cyclerion Therapeutics (CYCN) Expected to Announce Earnings on Tuesday

Cyclerion Therapeutics (NASDAQ:CYCN) will likely be releasing its results before the market opens on Tuesday, August 4th. Analysts expect Cyclerion Therapeutics to post earnings of ($7.10) per share and revenue of $1.50 million for the quarter.

Cyclerion Therapeutics (NASDAQ:CYCN) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($17.20) by $16.44. Cyclerion Therapeutics had a negative return on equity of 62.10% and a negative net margin of 170.11%. On average, analysts expect Cyclerion Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cyclerion Therapeutics Stock Performance

Shares of CYCN opened at $3.48 on Tuesday. The business has a 50-day moving average of $3.33 and a 200 day moving average of $2.54. Cyclerion Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $8.48. The firm has a market cap of $15.07 million, a P/E ratio of -2.56 and a beta of 1.74.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. 75.62% of the stock is owned by institutional investors.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.